Cargando…

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis

Melanoma cells have been shown to respond to BRAF inhibitors; however, intrinsic and acquired resistance limits their clinical application. In this study, we performed RNA-Seq analysis with BRAF inhibitor-sensitive (A375P) and -resistant (A375P/Mdr with acquired resistance and SK-MEL-2 with intrinsi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Jun-Ho, Hwang, Sung-Hee, Cho, Hyun-Soo, Lee, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Applied Pharmacology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513187/ https://www.ncbi.nlm.nih.gov/pubmed/30293252 http://dx.doi.org/10.4062/biomolther.2018.133

Ejemplares similares

Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition
por: Yeom, Hojin, et al.
Publicado: (2021)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
por: Savoia, Paola, et al.
Publicado: (2020)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
por: Proietti, Ilaria, et al.
Publicado: (2020)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations
por: Ho, Yu-Jui, et al.
Publicado: (2018)

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
por: Turajlic, S., et al.
Publicado: (2014)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer
por: Lee, Seung-Hyun, et al.
Publicado: (2013)

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
por: Falchook, G.S., et al.
Publicado: (2013)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients with Acromegaly
por: Kim, Hee Kyung, et al.
Publicado: (2014)

Analysis of optimized DNase-seq reveals intrinsic bias in transcription factor footprint identification
por: He, Housheng Hansen, et al.
Publicado: (2013)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

BRAF inhibitors in clinical oncology
por: Morris, Van, et al.
Publicado: (2013)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing
por: Han, Jiyeon, et al.
Publicado: (2021)

Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors
por: Martinez, Ramon, et al.
Publicado: (2022)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Transcriptome analysis based on RNA-seq of common innate immune responses of flounder cells to IHNV, VHSV, and HIRRV
por: Kim, Kwang Il, et al.
Publicado: (2020)

Intrinsic and acquired resistance mechanisms in enterococcus
por: Hollenbeck, Brian L., et al.
Publicado: (2012)

Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
por: Xiao, Jingjing, et al.
Publicado: (2018)

Intrinsic entropy model for feature selection of scRNA-seq data
por: Li, Lin, et al.
Publicado: (2022)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
por: Sinnberg, Tobias, et al.
Publicado: (2016)

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
por: Caporali, Simona, et al.
Publicado: (2017)

Hyperplastic Polyposis Syndrome Identified with a BRAF Mutation
por: Ahn, Hyung Su, et al.
Publicado: (2012)

Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A
por: Kang, So-mi, et al.
Publicado: (2021)

Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
por: Misek, SA, et al.
Publicado: (2019)

Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
por: Ng, Thomas S. C., et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mdv9q7breo6jt54ph1javolib1